Korean J Urol.  2006 Apr;47(4):362-367. 10.4111/kju.2006.47.4.362.

Free PSA and the Free PSA to Total PSA Ratio as a Predictor of Response to Hormone Treatment for Metastatic Prostate Cancer

• Yoon CY

• KMID: 1997143
• DOI: http://doi.org/10.4111/kju.2006.47.4.362

Abstract

PURPOSE
In this study we analyzed the changes of fPSA and f-PSA% and its prognostic significance in course of hormone treatment for metastatic prostate cancer.
MATERIALS AND METHODS
We retrospectively analyzed 75 patients with metastatic prostate cancer who received maximal androgen deprivation therapy and in whom the fPSA and f-PSA% had been serially checked for at least 1 year. The patients were divided into two groups: those patients with biological recurrence within 1 year, and those patients showing sensitivity to hormone therapy for longer than one year. Changes of the fPSA and f-PSA% in each group were analyzed in correlation with such prognostic factors as the PSA level and the Gleason sum.
RESULTS
The initial PSA levels in each group were 508.0+/-331.4ng/ml and 39.8+/-7.6ng/ml, respectively and the fPSA levels were 59.4+/-19.4ng/ml and 6.7+/-4.1ng/ml, respectively; the group with early biological recurrence had significantly higher intial PSA and fPSA levels. The initial f-PSA% was relatively lower in the patients with early recurrence (0.123+/-0.41 vs 0.159+/-0.37, respectively), but the difference was not statistically significant. The PSA nadir and the fPSA nadir in the early recurrence group were 6.1 10.1ng/ml and 0.89 3.9ng/ml, respectively, and these were significantly higher compared to those values of the hormone sensitive group, i.e., 2.4+/-8.4ng/ml and 0.41+/-0.2ng/ml, respectively. In the early recurrence group, the f-PSA% changed from 0.123 to 0.092 and it gradually decreased during treatment. On the contrary, in the hormone sensitive group, the f-PSA% continuously increased during treatment, from 0.159 to 0.172. CONCLUSIONS: These findings suggest that fPSA and f-PSA% are influenced by hormone treatment and the pattern of changes in the fPSA and f-PSA% are different according to the responsiveness to hormone treatment.

Keyword

Prostate-specific antigen; Prostate cancer; Hormone replacement therapy

MeSH Terms

Hormone Replacement Therapy
Humans
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Recurrence
Retrospective Studies
Prostate-Specific Antigen

Reference

1. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology. 2002. 60:4–9.

2. Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol. 2001. 165:1549–1553.

3. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA). Prostate. 1996. 7:64–69.

4. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10ng/ml. range. J Urol. 2002. 168:504–508.

5. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol. 2005. 174:2150–2153.

6. Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0ng/ml. Urology. 2003. 61:760–764.

7. Miele ME. Percent free PSA as an additional measure in a prostate cancer screen. Clin Lab Sci. 2001. 14:102–107.

8. Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology. 2004. 64:1160–1164.

9. Bjork T, Bjartell A, Abrahamsson PA, Hulkko S, di Sant Agnese A, Lilja H. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology. 1994. 43:427–434.

10. Jung K, Brux B, Knabich A, Lein M, Sinha P, Schnorr D, et al. A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem. 1999. 45:422–424.

11. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem. 1998. 44:1216–1223.

12. Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer. 1997. 74:630–636.

13. Gregorakis AK, Malovrouvas D, Stefanakis S, Petraki K, Scorilas A. Free/total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. Clin Chim Acta. 2005. 357:196–201.

14. Zackrisson B, Ulleryd P, Aus G, Lilja H, Sandberg T, Hugosson J. Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology. 2003. 62:278–281.

15. Jung K, Meyer A, Lein M, Rudolph B, Schnorr D, Loening SA. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol. 1998. 159:1595–1598.

16. Fujinami K, Miura T, Takizawa A, Osada Y, Kawakami S. Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10ng/ml. Nippon Hinyokika Gakkai Zasshi. 2005. 96:475–479.

17. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer. 1997. 79:104–109.

18. Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol. 1997. 158:2188–2192.

19. Crook JM, Bunting PS. Percent free prostate-specific antigen after radiotherapy for prostate cancer. Urology. 1998. 52:100–105.

20. Morote J, Encabo G, Lopez MA, De Torres IM. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. BJU Int. 1999. 83:1003–1006.

21. Aus G, Becker C, Lilja H, Khatami A, Pihl CG, Hugosson J. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Scand J Urol Nephrol. 2003. 37:466–470.

22. Li W, Ren Y, Mee V, Wong PY. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin Biochem. 1999. 32:31–37.

23. Grossklaus DJ, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol. 2002. 7:195–198.

24. Wymenga LF, Duisterwinkel FJ, Groenier K, Visser-van Brummen P, Marrink J, Mensink HJ. Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios. Scand J Urol Nephrol. 2000. 34:181–187.

25. Anfossi E, Rossi D, Grisoni V, Sauvan R, Bladou F, Serment G. What is the role of the correspondence of free PSA/total PSA in the staging of local prostate cancer? Series of 50 radical prostatectomy cases. Prog Urol. 1999. 9:479–482.

26. Stein A, Barak M, Mecz Y, Rubinov R, Lurie A. Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists. Eur Urol. 1997. 32:64–68.

27. Espana F, Martinez M, Royo M, Estelles A, Alapont JM, Navarro S, et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int. 2002. 90:672–677.

28. Morote J, Lorente JA, Raventos CX, Lopez MA, Encabo G, De Torres I, et al. Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer. Actas Urol Esp. 1998. 22:835–839.

29. Tanaka M, Murakami S, Suzuki N, Shimazaki J. Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. Int J Urol. 2000. 7:83–87.